A Human Proteome Array Approach to Identifying Key Host Proteins Targeted by Toxoplasma Kinase ROP18*

Zhaoshou Yang†¶¶, Yongheng Hou‡¶¶, Taofang Hao‡, Hee-Sool Rho§, Jun Wan¶, Yizhao Luan∥∥, Xin Gao‡‡, Jianping Yao§§, Aihua Pan‡, Zhi Xie∥, Jiang Qian¶, Wanqin Liao‡∥, Heng Zhu§∥, and Xingwang Zhou‡∥∥

Toxoplasma kinase ROP18 is a key molecule responsible for the virulence of Toxoplasma gondii; however, the mechanisms by which ROP18 exerts parasite virulence via interaction with host proteins remain limited to a small number of identified substrates. To identify a broader array of ROP18 substrates, we successfully purified bioactive mature ROP18 and used it to probe a human proteome array. Sixty-eight new putative host targets were identified. Functional annotation analysis suggested that these proteins have a variety of functions, including metabolic process, kinase activity and phosphorylation, cell growth, apoptosis, cell death, and immunity, indicating a pleiotropic role of ROP18 kinase. Among these proteins, four candidates, p53, p38, UBE2N, and Smad1, were further validated. We demonstrated that ROP18 targets p53, p38, UBE2N, and Smad1 for degradation. Importantly, we demonstrated that ROP18 phosphorylates Smad1 Ser-187 to trigger its proteasome-dependent degradation. Further functional characterization of the substrates of ROP18 may enhance understanding of the pathogenesis of Toxoplasma infection and provide new therapeutic targets. Similar strategies could be used to identify novel host targets for other microbial kinases functioning at the pathogen-host interface. Molecular & Cellular Proteomics 16: 10.1074/mcp.M116.063602, 469–484, 2017.

Toxoplasma gondii is a widespread pathogen parasite that infects a broad range of warm-blooded animals, including humans, causing severe toxoplasmosis in congenitally infected newborns and immunocompromised individuals (1, 2). Despite progress in the clinical management of this disease, important limitations remain, such as the lack of a commercial vaccine and imperfect drugs for toxoplasmic encephalitis (3, 4). Therefore, the discovery of novel targets and effective therapeutic strategies against toxoplasmosis is of acute importance.

During infection, T. gondii delivers numerous effectors into the parasitophorous vacuole and the host cytoplasm to co-opt the host cell for survival and replication (5). Among these effectors, ROP18 is suggested to be a key determinant responsible for the virulence of T. gondii (6, 7). ROP18 is a member of the ROP2 subfamily of protein kinase, which is secreted from apical organelle rhoptries into the host cell and localizes to the parasitophorous vacuole membranes (PVMs) during invasion (8). ROP18 is a Ser/Thr protein kinase, which mediates parasite virulence through targeting and phosphorylating host proteins (9).

In recent years, several substrates have been identified for ROP18 (10–13). ROP18 has been reported to phosphorylate the immunity-related GTPases, Irga6 and Irgb6, preventing their accumulation at PVMs and the clearance of parasites at an early stage after infection (10, 11). Given the absence of an immunity-related GTPase system in humans, it is likely that additional host defense systems may be targeted by ROP18. Using a yeast two-hybrid screening, Yamamoto et al. (12)
have identified another target of ROP18, the host endoplasmic reticulum-bound transcription factor ATF6β. ROP18 phosphorlylates ATF6β and triggers its proteasomal degradation, and thus it impairs the ATF6β-dependent immune responses at a later stage after infection (12). More recently, a study showed that via phosphorylation, ROP18 mediates ubiquitin-dependent degradation of p65, leading to suppression of the NF-κB pathway to limit expression of proinflammatory cytokines (13). Although Cheng et al. (14) have identified several ROP18-interacting human proteins using a yeast two-hybrid technology, it remains unclear whether these proteins are substrates of ROP18. Overall, these studies have provided important insights into the basis of ROP18-mediated parasite virulence; however, the full scope of ROP18’s contribution to virulence remains poorly understood. Identification of other ROP18 substrates is needed to more completely understand the mechanisms of ROP18-mediated augmentation of the disease.

Functional proteome array technology has been established as a powerful tool for proteome-wide identification of substrates for a variety of post-translational modification enzymes, such as protein kinases, acetyltransferases, and ubiquitin E3 ligases (15–17). For example, functional human protein microarrays have been used to successfully identify substrates of >370 human kinases (18–24). In this study, we utilized a human proteome array (i.e. HuProt), composed of >16,000 human proteins, to globally identify host cell proteins that could be phosphorylated by ROP18 kinase, and we found multiple potential host cellular substrates involved in a wide range of functions. Four of these, p53, p38, UBE2N, and Smad1, were selected for further in vitro and in vivo characterization.

MATERIALS AND METHODS

Cells and Parasites—All parasites were maintained by serial passage in human foreskin fibroblasts (HFFs) as described previously (25). Tachyzoites of the RH strain and ROP18 knockout (ROP18-KO) RH strain of T. gondii were kindly provided by Professor Vern B. Carruthers (University of Michigan School of Medicine). Tachyzoites of the T. gondii RH strain parasites with the forward primer 5′-ACCGTCGTC-GGAATGCGTTTAG-3′ and the reverse primer 5′-CAATAAGCCATC-CGTGAGAAG-3′. The fragment of ROP18 lacking the N-terminal signal peptide and prodomain (ROP18Δ383, amino acids 83–539, numbering based on the second ATG codon) was further amplified with the primers 5′-GGGACAAGTTTGTACAAAAAAGCAGGCTT- CGAAGGGGTCAACACCCGGG-3′ and 5′-GGGACACGCTTGTCAG- AACAAAACCTGGGTATTTATGTGTGAGAGGTTC-3′. Underlines indicate the recombinase sites attB1 and attB2, respectively. GST-ROP18Δ383 and V5-ROP18Δ383 plasmids were constructed by utilizing the Gateway cloning system (Invitroge). Briefly, the PCR product was cloned into pDONR201 vector through BR recombination reaction to construct the entry clone (pDONR201-ROP18Δ383). After confirming by restriction enzyme digestion and sequencing, ROP18Δ383 was subcloned from the entry clone into the pEGH-A vector that produces GST-His6 fusion protein (GST-ROP18Δ383) or pcDNA3.1/nV5-DEST vector that produces V5-tagged protein (V5-ROP18Δ383) through LR recombination reaction. The kinase-dead ROP18 mutant (D394A) (ROP18Δ383-KD) was generated using the QuikChange® Lightning Multi Site-directed mutagenesis kit (Agilent Technologies) with the primer 5′-ATTGTGCTACAGGCTCCTAACAAGCCGGG-3′ using the pDONR201-ROP18Δ383 plasmid as a template. Then ROP18Δ383-KD was subcloned from the entry clone into pEGH-A vector to construct GST-ROP18Δ383-KD or pcDNA3.1/nV5-DEST to construct V5-ROP18Δ383-KD, through LR recombination reaction. Total RNA was extracted from 293T cells by TRIzol reagent (Invitrogen), and the cDNA was synthesized by Moloney murine leukemia virus reverse transcription kit (Promega). The human TP53 cDNA (GenBank™ accession no. NM_000546) was amplified by PCR with the following primers, 5′-CGGGATCTCATGAGAGCGCCAGTCAAG-3′ and 5′-CGGGAATTCTCGATGTCGAGGTCCCATTTCC-3′, and cloned into pCMV-Tag2B vector to produce a FLAG-tagged protein (FLAG-p53) with BamHI and EcoRI enzyme digestion sites (underlined). The human SMAD1 cDNA (GenBank™ accession no. NM_00103688) was amplified with primers 5′-CGGGGATCCATGAGAGCGCCAGTCAAG-3′ and 5′-CGCAAGCTTTTATATATAGAGATAGAAATG-3′ and cloned into pCMV-Tag2B vector to produce a FLAG-tagged protein (FLAG-Smad1) or bacterial expression vector pET-30a to produce a Histagged protein (His-Smad1), using the BamHI and HindIII digestion sites (underlined). Modifications in SMAD1 were induced using the QuikChange® Lightning Multi Site-directed mutagenesis kit using the following primers: S187A, 5′-CCACCGTTTCCACTCGTCCACTAAGGACTGAAT-3′; S195A, 5′-CAGATTACCCAAAGCCGCT-CCTGGAGACGC-3′; S206A, 5′-CCTCTACCTACGGCCGCTC-3′; and S214A, 5′-CAGACGCTAGACGAGGCCCCTTTTCCAGATG-3′. The ROP18Δ383-GFP plasmid was kindly provided by Professor Jian Du (Anhui Medical University, Anhui, China) (13).
Protein Microarray Identifying Novel ROP18 Kinase Substrates

URA/glucose liquid medium at 30 °C with shaking to saturation. The saturated cultures were diluted 1:25 into SC-URA/raf/nose liquid medium, and the cultures were incubated at 30 °C with shaking. When the A_600 of cultures reached 0.7–0.9, the cultures were induced with 2% galactose for 4 h at 30 °C. Then the yeast cells were harvested and lysed with zirconia beads (0.5 mm diameter from BSG, Germany) in cold lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EGTA, 10% glycerol, 0.1% Triton X-100, and 0.1% β-mercaptoethanol, 1 mM PMSF, and protease mixture inhibitors). GST fusion proteins were bound to glutathione-Sepharose (Amersham Biosciences) for 1 h at 4 °C and washed four times for 15 min each time with wash I buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1 mM EGTA, 0.1% Triton X-100, 0.1% β-mercaptoethanol, 0.5 mM PMSF, and protease mixture inhibitors) and two times with wash II buffer (50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EGTA, 10% glycerol, 0.1% β-mercaptoethanol, and 0.5 mM PMSF) and eluted in elution buffer (100 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM MgCl_2, 20 mM glutathione, and 20% glycerol). Eluates were collected and stored at −80 °C for further experiments.

Dot Blot Kinase Assay—A dot blot kinase assay was performed as described previously with slight modifications (30). Briefly, 10 μl of GST-ROP18 or GST-ROP18-KD protein solution was added to a 96-well plate with 10 μl of kinase assay buffer containing 2 μCi of [γ-32P]ATP and incubated for 30 min at 30 °C. Then 5 μl of reaction mixture was dotted onto the nitrocellulose membrane. After air-drying, the membrane was washed three times with TBST buffer (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, and 0.1% Tween 20). After air-drying again, the membrane was exposed to the X-ray film.

Protein Array Phosphorylation Assays—The HuProt array was fabricated by spotting down 16,368 unique full-length human recombinant proteins in duplicate along with several control proteins provided by CDBI Laboratories, Inc. (31, 32). The protocol for phosphorylation assays on HuProt arrays was modified from that of previous publications (23, 24). Briefly, HuProt arrays were preincubated in Superblock (Pierce) containing 0.2% BSA and 1% Triton X-100 for 1 h at room temperature. Purified GST-ROP18 or GST-ROP18-KD recombinant proteins were diluted with kinase buffer (50 mM Tris-HCl, pH 7.4, 20 mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl_2, 1 mM DTT, 1 mM EGTA, and 20 mM cold ATP) and [γ-32P]ATP (33.3 μM final concentration). Duplicate HuProt arrays were incubated with the kinase mixture in a humidity chamber for 30 min at 30 °C. Slides were subjected to three 10-min washes with TBST buffer (25 mM Tris-HCl, pH 7.4, 3 mM KCl, 150 mM NaCl, 0.05% Tween 20) and three 10-min washes with 10 mM Tris-HCl, pH 7.4, and 0.5% SDS, rinsed briefly with doubly distilled water, and spun dry. Control slides were incubated with kinase buffer without kinase and processed in parallel. The slides were exposed to X-ray films that were scanned at 1,800 pixels/inch and analyzed using GenePix 3.0 (Molecular Devices). The experiments were performed in duplicate, and only those that were reproducible were scored as positives.

Protein Microarray Data Analysis—Following chip scanning, background correction was performed to obtain the signal intensity value for each spot using the ratio of foreground to background signals. Then, between-array normalization was performed. To identify positive hits on the microarrays, we estimated the standard deviation from the signal intensity distribution, as described in detail previously (33). Cutoff values of 2.0 and 2.5 standard deviations above the mean were chosen in this study. For proteins printed in duplicate, the ones with both spots meeting our defined cutoff were defined as positive hits. Finally, because it is impossible to distinguish signals arising from auto-phosphorylation events and trans-phosphorylation events, we conducted negative control experiments during each set of assays to identify proteins that underwent auto-phosphorylation on the protein microarrays. The proteins that exhibited auto-phosphorylation activity in the negative control experiments were excluded from the substrate list for further analysis. These proteins were obtained using cutoff values of 2.0 standard deviations above the mean. Background correction and between-array normalization were conducted using limma package (34).

Gene Ontology and Functional Protein Analysis—We calculated the occurrence frequency of each GO term or KEGG pathway within foreground (e.g. ROP18 substrates) and background gene groups (e.g. the whole human genome), respectively. Then we used a hypergeometric model to evaluate the statistical significance of a comparison between foreground and background, followed by multiple-test Bonferroni correction (for GO) or false discovery rate correction (for KEGG pathway). A GO term or KEGG pathway was defined as an enriched one if its frequency in the foreground was larger than that in the background and its corrected p value was less than 0.05.

Because many detailed GO terms were found enriched for ROP18 substrates, we merged them into five general groups as follows: metabolic process, kinase activity/phosphorylation, response to growth factor, apoptotic process/cell death, and immune system process. We merged associated GO terms into these five categories and then re-calculated the occurrence frequencies for the foreground and background gene groups, respectively, and we obtained corresponding p values based on hypergeometric distribution.

Similarity Comparison with ROP18—We used the database, PhosphoNetworks, to investigate phosphorylation substrates of 289 kinases. The hypergeometric probability of finding a certain number of common targets between kinase i and ROP18 is given in Equation 1.

\[ p(m|S_{Di}; K_i, n) = \frac{\binom{n}{m} \binom{S_{Di} - n}{K_i - m}}{\binom{S_{Di}}{K_i}} \]  
(Eq. 1)

where \( S_{Di} \) is the total number of unique substrates in the database; \( K_i \) is the number of substrates of kinase i; \( n \) is the number of ROP18 substrates detected in the database; and \( m \) is the number of common targets between ROP18 and kinase i.

In Vitro Infection—Cells were infected by tachyzoites of RH strain, as described previously (35) with slight modifications. Briefly, cells were plated in 12-well plates 24 h before infection. Fresh tachyzoites of the RH strain were added to plates at a density of 5.0 × 10^5 per well. After 5 h of infection, uninvaded parasites were washed with pre-warmed PBS and refilled with fresh medium. At 36 h post-infection, total cell lysates were harvested for further experiments.

Transfection—Transfections were carried out using Lipofectamine 2000 (Invitrogen) as instructed by the manufacturer. 293T cells (2 × 10^5 per well) were seeded into 12-well plates coated with poly-L-lysine (Sangon Biotech, Shanghai, China). 24 h later, cells were incubated with plasmids mixed with Lipofectamine reagent in DMEM medium for 6 h. Then the DMEM medium was replaced with complete DMEM. Cells were harvested at the indicated time points and used for further experiments.

Immunofluorescence Staining—Immunofluorescence staining was performed as described previously with slight modifications (25, 28). Briefly, HeLa monolayers grown on coverslips were transfected with V5-ROP18 alone or together with FLAG-p53. At 24 h after transfection, cells were infected with tachyzoites of T. gondii. 24 h after infection, cells were fixed with 4% paraformaldehyde for 10 min and permeabilized with 0.02% digitonin in PBS for 10 min. After blocking with 3% BSA in PBS for 30 min, cells were incubated with primary anti-V5 and anti-FLAG (or anti-p38 MAPK) antibodies at 4 °C overnight followed by incubation with Alexa Fluor®488 goat anti-mouse IgG and Alexa Fluor®555 goat anti-rabbit IgG. Coverslips were mounted with ProLong® Gold antifade reagent containing DAPI (Life Technologies, Inc.) that was used for DNA visualization. Slides were...
viewed under an inverted fluorescence microscope (OLYMPUS 1X71) with appropriate filters.

**GST Pulldown Assay**—GST pulldown was performed as described previously (36). GST-ROP18<sup>83</sup> and GST tag proteins were purified and conjugated to glutathione-Sepharose beads. 293T cells were harvested and lysed in PBS buffer containing 1.0% Nonidet P-40, 0.5% deoxycholic acid sodium, and protease inhibitor mixtures. After incubation on ice for 25 min, the lysate was centrifuged at 13,000 × g for 25 min at 4 °C, and the supernatant was collected. The supernatant was buffer exchanged with PBS, pH 7.4, containing protease inhibitor mixtures using the Amicon<sup>R</sup> Ultra 10K device (Millipore) and then incubated with GST-ROP18<sup>83</sup>-conjugated or GST-conjugated beads for 4 h at 4 °C. After washing three times with PBS containing 0.1% Triton X-100, beads were eluted in elution buffer (100 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 20 mM glutathione, and 20% glycerol). Eluates were boiled for 5 min with Laemmli buffer and analyzed by Western blotting.

**Coimmunoprecipitation**—Immunoprecipitation assay was performed using the coimmunoprecipitation kit (Thermo Scientific Pierce) according to the manufacturer’s instructions. Briefly, cells were lysed in IP lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 5% glycerol) on ice for 25 min and centrifuged at 13,000 × g for 25 min at 4 °C. Corresponding primary antibodies were covalently coupled onto the AminoLink Plus Coupling Resin. Cell lysates were incubated with the coupled resin for 4 h at room temperature. The resin was washed once with IP lysis buffer and two times with conditioning buffer and eluted with elution buffer provided in the kit. Eluates were analyzed by Western blotting with the indicated antibodies.

**Western Blotting**—Cells were harvested and lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM EDTA, and 1% Na<sub>2</sub>VO<sub>4</sub>) supplemented with phosphatase inhibitor mixture on ice for 20 min. Total cell lysates were resolved by SDS-PAGE and transferred to PVDF membranes (Millipore). The membranes were blocked for 1 h in 5% non-fat dry milk in TBST buffer (100 mM Tris-HCl, pH 7.5, 0.9% NaCl, and 0.1% Tween 20) and incubated with primary antibodies diluted in 3% BSA at 4 °C overnight. Then the membranes were incubated with HRP-conjugated secondary antibodies and detected with ECL Plus (Millipore).

**In Vitro Phosphorylation Assay**—The His-tagged full-length Smad1 was expressed in Escherichia coli BL21 (DE3) strain and purified by using Ni<sup>2+</sup>-Sepharose beads (Qiagen) as described previously (37). The GST-tagged ROP18<sup>83</sup> and GST-ROP18<sup>83</sup>-KD recombinant proteins were purified as described above. For the in vitro phosphorylation assay, GST-ROP18<sup>83</sup> or GST-ROP18<sup>83</sup>-KD recombinant proteins were incubated with purified recombinant His-Smad1 in kinase buffer (50 mM Tris-HCl, pH 7.4, 20 mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 1 mM DTT, 1 mM EGTA, and 20 μM ATP) with 0.5 μCi of [γ-<sup>32</sup>P]ATP. The reaction mixtures were incubated at 30 °C for 30 min and terminated by adding SDS-PAGE sample buffer and heating immediately at 95 °C for 5 min. Proteins were analyzed by SDS-PAGE, and the gel was exposed to X-ray films after dried.

**RESULTS**

**Expression and Purification of ROP18 Recombinant Proteins**—To ensure purification of sufficient amounts of active ROP18 kinase proteins to carry out phosphorylation reactions on the HuProt arrays, we employed the budding yeast as an expression and purification system, as it has been successfully used to purify >400 active human and viral kinases in our previous studies (18, 22). The GST-tagged ROP18<sup>83</sup> and the kinase-dead ROP18 mutant (D394A) (ROP18<sup>83</sup>-KD), a negative control, were expressed in yeast cells and purified (Fig. 1A). As judged by Coomassie staining, both GST-tagged ROP18<sup>83</sup> and ROP18<sup>83</sup>-KD proteins showed a single band at the expected molecular weights, indicating that both proteins were successfully purified with high purity (Fig. 1B). To examine whether the purified ROP18<sup>83</sup> retained its kinase activity, we employed auto-phosphorylation reactions using [γ-<sup>32</sup>P]ATP as a labeling reagent. Commercially available EGFR kinase proteins were used as a positive control. Both ROP18<sup>83</sup> and EGFR kinases showed auto-phosphorylation activity, whereas ROP18<sup>83</sup>-KD did not, as demonstrated by the dot blot kinase assay (Fig. 1C). Together, these results confirmed that the purified ROP18 kinase was active and validated the kinase-dead mutant as an inactive negative control.

**Identification of ROP18 Substrates in Vitro**—To better understand the contribution of ROP18 to parasite virulence via its kinase activity, we set out to systematically identify the
ROP18 substrates using the HuProt arrays (version II) that contain 16,368 unique, full-length human proteins that were individually purified (Fig. 2, A and B) (31, 32). Purified GST-ROP18A83 and GST-ROP18A83-KD proteins were separately incubated with a pre-blocked HuProt array in a generic kinase reaction buffer containing [γ-32P]ATP. After the kinase reaction, protein microarrays were washed to remove added proteins and unincorporated [γ-32P]ATP followed by exposure to X-ray films. The films were then scanned, and bioinformatics analysis and partial validation were performed. B, representative image of the HuProt array. Individually purified human proteins tagged with GST were spotted in duplicate on a single slide, and the immobilized human proteins were visualized by probing with anti-GST antibody. C, representative photographs of X-ray films. After the kinase reactions on the HuProt arrays, the phosphorylation signals were detected by exposure of the slides to a piece of X-ray film. Developed X-ray film was then scanned, and the enlarged images of p53, MAPK11 (i.e. p38), UBE2N, and Smad1 protein dots are shown.

| Protein | Protein (continued) | Protein (continued) |
|---------|---------------------|---------------------|
| ANUBL1  | MAP3K5              | RBBP5               |
| BCL11A  | MAPK10              | REM1                |
| C18orf25| MAPK11              | RFK                 |
| C4orf119| MAPK9               | RFX4                |
| CLK2    | MOSPD3              | RNF25               |
| CNBP    | NADK                | SFRS12              |
| CSNK1G3 | NAP1L1              | SMAD1               |
| CSRP3   | NME2                | SMYD2               |
| CYB5B   | NPM2                | SRPX2               |
| DAPK2   | OSBP6L              | SSPN                |
| DIXDC1  | PACSIN2             | SUPT6H              |
| FAM5B   | PARN                | TBC1D16             |
| FLT1    | PAX9                | THUMPD3             |
| FN3K    | PCDHGC3             | TP53                |
| GSK3B   | PDPK1               | TSSC4               |
| HARS    | PEL3                | UBE2N               |
| HDGF2   | PLEK2               | WDR45               |
| HNRPK   | PRAC                | XRC4                |
| IRF1    | PRKAR1A             | ZBTB22              |
| KIF3C   | PRKCA               | ZMYM3               |
| KLF11   | PRKRA               | ZNF16               |
| KPNA2   | PSM7D               | ZNF641              |
| MAGB4   | RAB43               |                     |

Because a common means for a pathogen to hijack the cellular pathways is by targeting multiple components of the same host signaling pathways (20), we first performed the STRING
Protein Microarray Identifying Novel ROP18 Kinase Substrates

Fig. 3. Bioinformatics analysis of the identified in vitro substrates of ROP18. A, integration of known PPI relationships revealed that 32 of the 68 identified substrates of ROP18 form a highly connected PPI network. TP53 is located as the most connected hub in the center of the PPI network. B, GO analysis demonstrated that 68 ROP18 targets (left panel), especially 32 of them with annotated PPI relationships (right panel), are significantly enriched in some biological functions, e.g. metabolic process, kinase activity/phosphorylation, response to growth factor, apoptotic process/cell death, and immune system process. C, ROP18 targets are over-represented in some signaling pathways. Examples of the insulin signaling and MAPK signaling pathways are shown. Identified ROP18 substrates are indicated by circles with GO terms annotated in different colors using the same code as A, D. Using the M3 algorithm, ROP18 was found to specifically recognize an acidic phospho-motif, which is most similar to CSNK2A1. E, comparison of identified substrates using the protein microarray approach revealed 14 human kinases that share a significant portion of targets as ROP18. p values of the statistical significance of each human kinase are shown in the bottom panel.

analysis (STRING.org), which integrates known protein-protein interaction (PPI) information, against the 68 in vitro substrates of ROP18, to determine whether there is any significant PPI network among these substrates (Fig. 3A) (38). As expected, 32 of the 68 substrates of ROP18 formed a tightly connected PPI network with 54 edges (i.e. known PPI relationships). Interestingly, p53 (i.e. TP53) is identified as the central hub located in the middle of the PPI network with 20 edges. Overall, 31 of the 68 substrates were also identified as either the kinases (Fig. 3A, circled in red) or kinase substrates...
Protein Microarray Identifying Novel ROP18 Kinase Substrates

(Fig. 3A, with asterisk) in our previous study, in which an activity-based kinase-substrate relationship (KSR) network was established (18, 39). Interestingly, 8 of the 31 ROP18 substrates were protein kinase themselves, whereas only 105 of the total 1,967 substrates also phosphorylated others in the KSR networks. This phenomenon is more pronounced in the PPI network formed by the 32 ROP18 substrates, 11 are known protein kinases and 21 are found in the KSR networks. Note that the majority of the KSR was determined by performing phosphorylation reactions on an early version of the human protein microarrays, each composed of ~4,200 unique proteins (18, 39). Taken together, these analyses indicate a tendency of ROP18 to act as a master kinase that regulates many host kinases and signaling components (p = 1.2E-4).

Second, we performed Gene Ontology (GO) analysis to determine possible roles of ROP18 in pathogen-host interactions. We found that the 68 ROP18 substrates were significantly enriched in following biological functions: metabolic process (p = 1.2E-5); kinase activity or phosphorylation (p = 5.6E-6); response to growth factor (p = 5.0E-5); apoptotic process or cell death (p = 6.1E-4), and immune system process (p = 2.9E-4) (Fig. 3B). When focusing on the 32 substrates that form a highly connected PPI network, the p values of the corresponding GO terms were further improved by at least 1.7 logs (right panel, Fig. 3B). This analysis suggests that ROP18 is likely to play a pleiotropic role as a master kinase that is capable of regulating multiple signaling pathways in parallel.

Indeed, ROP18 substrates were found enriched in several specific signaling pathways, such as the insulin signaling and mitogen-activated protein kinase (MAPK) signaling pathways. For instance, ROP18 was found to phosphorylate multiple kinases, including MAPK9, MAPK10, PDPK1, GSK3β, and PRKAR1A, which are the downstream components of the insulin signaling pathway (p = 8.3E-4) with multiple physiological outcomes, such as protein synthesis, glycosogens, and anti-lipolysis (upper panel, Fig. 3C). Similarly, ROP18 seems to regulate two parallel MAPK signaling pathways (p = 1.2E-3) by targeting MAPKKK (i.e. MAP3K5) and p38 (i.e. MAPK11) and by targeting JNK2/3 (i.e. MAPK9 and MAPK10), which converge at p53 that leads to transcription activation of the p53 target genes (lower panel, Fig. 3C).

To better understand how ROP18 recognizes its substrates, we next employed a previously reported M3 algorithm, which integrates the phosphorylation sites identified with mass spectrometry approaches with ROP18’s substrates, and we determined the phosphorylation motif logo of ROP18 as (S/T)XXXXXDE (Fig. 3D) (18, 39). After searching the KSR database, we found that the acidic phospho-motif recognized by ROP18 is most similar to that of the catalytic α subunit of casein kinase 2 (i.e. CSNK2A1), which is well known to be involved in many cellular processes, including apoptosis. Like ROP18, CSNK2A1 was also identified as a master kinase (p = 0.025), which tends to phosphorylate many other kinases.

Because a common theme utilized by pathogenic kinases is to imitate the host counterparts, we directly compared the substrate similarity of ROP18 with the 289 human kinases in the PhosphoNetworks database. We observed that 14 human kinases showed a significant similarity (p < 0.01) with ROP18 in terms of substrate specificity (Fig. 3E). Moreover, four of these 14 kinases, including NIM1, PRKX, PRKCH, and GSK3β, have a strong tendency to phosphorylate other kinases. This is significant (p < 0.05) because only 57 of the 289 tested kinases showed a similar behavior. This observation suggests again that ROP18 is likely to mimic human master kinases rather than general kinases. Of the 14 kinases, STK3 showed the lowest p value, at least 10-fold lower than the second best one. STK3 (also known as MST2) is a proapoptotic serine/threonine kinase and plays a critical role in the Hippo-YAP signaling pathway (40). In response to proapoptotic molecules, STK3 is activated by caspase cleavage of the auto-inhibitory domain, and the cleaved N-terminal portion of STK3 goes to the nucleus and forms the active kinase dimer. A recent study by Wu et al. (41) suggested that ROP18 might manipulate the host mitochondrial apoptosis pathways. They observed that overexpression of T. gondii ROP18 significantly suppressed 293T cell apoptosis induced by actinomycin D and maintained mitochondrial membrane potential and integrity. Interestingly, STK3 recognizes a very different phospho-motif (i.e. HRXX(S/T), where X is any amino acid) than ROP18, suggesting that ROP18 phosphorylates different Ser/Thr residues of these shared substrates, which might lead to different physiological outcomes of the substrates. Two other kinases, RPS6KA6 and PRKX, were found to recognize a very similar acidic phospho-motif as ROP18. Although not much is known about PRKX functions in cells, RPS6KA6 (i.e. RSK4) is well characterized for its role in the neurotrophin signaling (42). RSK4 acts as a downstream kinase of ERK1/2 that activates cell differentiation and cell survival processes. Therefore, it is plausible that ROP18 hijacks RSK4’s role by phosphorylating the same downstream substrates of RSK4.

ROP18-mediated p53 Degradation via Phosphorylation—

On the basis of the study by Wu et al. (41) and the above bioinformatics analyses, we suspected that ROP18 might play an important role in anti-apoptosis. Intriguingly, p53 was identified as a novel substrate of ROP18 in our in vitro kinase assays and is located at the central hub position in the PPI network among the 32 ROP18 substrates (Fig. 3A), p53 is a master transcription factor and is known to respond to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism (43). p53 is also a well known tumor suppressor involved in immunity (44). It has been reported that infection from T. gondii induces endogenous p53 degradation; however, the exact molecular mechanism remains unknown (45, 46). Therefore, we decided to validate the relationship between ROP18 and p53 and determine the impact of ROP18 phosphorylation on p53.
To do so, immunofluorescence staining was performed. The results showed that p53 was colocalized with ROP18 at the PVMs in host cells (Fig. 4A), indicating that ROP18 and p53 might form a protein complex. To assess whether ROP18 interacts with p53, we performed a GST pulldown assay with recombinant GST-ROP18 H9004 83 protein. The results showed that GST-ROP18 H9004 83, but not the GST tag, was able to pull down p53 (Fig. 4B). Moreover, we performed coimmunoprecipitation assay and detected an interaction between ROP18 and p53 (Fig. 4C). We then investigated the effect of ROP18 on p53 expression. We observed that overexpression of ROP18 H9004 83 but not ROP18 H9004 83-KD significantly decreased the protein level of p53 (Fig. 4D), indicating that the kinase activity is essential for ROP18-mediated p53 degradation. In addition, ROP18 decreased the protein levels of p53 in a dose-dependent manner (Fig. 4E). To further demonstrate the specificity of ROP18-dependent p53 degradation, we cotransfected the FLAG-tagged p53 construct with different amounts of the V5-tagged ROP18 H9004 83 constructs to 293T cells. We found that overexpression of ROP18 H9004 83 caused dose-dependent degradation of the exogenous p53 protein (Fig. 4F). To investigate the impact of ROP18 on p53 expression in vivo, we infected 293T cells with wild-type (WT) RH or ROP18-Ty1 RH strain. Consistent with the previous studies (45, 46), we found that in 293T cells infected with WT RH strain led to a significant degradation of p53 protein. Additionally, infection of 293T cells with ROP18-Ty1 RH strain further extended the degradation (Fig. 4G). Taken together, these results demonstrated that ROP18 relies on its kinase activity to inhibit apoptosis in T. gondii-infected cells via targeting p53 for degradation.

ROP18-mediated p38 Degradation via Phosphorylation—MAPK signaling has been reported to be involved in the infection of T. gondii (47, 48). Intriguingly, our bioinformatics analyses suggested that ROP18 might regulate the MAPK pathways via targeting p38 (e.g. MAPK11). The p38 MAPKs are known to be activated by cytokines, LPS, and environmental stress and to be implicated in several processes, including cell survival, apoptosis, and immune function (49).
The p38 MAPK pathway has been related to *T. gondii* invasion (50, 51). To confirm the association between ROP18 and p38, immunofluorescence staining was performed. The results revealed a colocalization of p38 and ROP18 at the PVMs (Fig. 5A), indicating that ROP18 might form a complex with p38. To confirm this assumption, we performed a GST pulldown assay. The results showed that GST-ROP18\(^{\text{A83}}\) was able to pull down p38 (Fig. 5B), suggesting that ROP18 interacts with p38. We next investigated the potential impact of ROP18 on p38 in cells. We found that overexpression of ROP18\(^{\text{A83}}\) rather than ROP18\(^{\text{A83-KD}}\) significantly decreased the expression level of p38 protein (Fig. 5C), indicating that the kinase activity is required for ROP18-mediated p38 degradation. To further determine whether ROP18 affects the stability of p38 *in vivo*, 293T cells were infected with WT RH or ROP18-Ty1 RH strain. The results showed that infection with WT RH strain significantly reduced the p38 protein level as compared with that in un-infected cells, and infection with ROP18-Ty1 RH strain resulted in a more significant reduction of p38 protein level (Fig. 5D). Together, these results suggested that ROP18 targets p38 for degradation via phosphorylation.

**ROP18-mediated UBE2N Degradation via Phosphorylation**—Du et al. (13) reported that ROP18 inactivates the NF-κB pathway via phosphorylation and degradation of p65. Interestingly, we identified another upstream regulator of NF-κB pathway, UBE2N (52, 53), as a putative substrate of ROP18. UBE2N is also found as a hub in the PPI network that is directly connected to p53, PDK1, PELI3, ZFAND4, and NME2 (Fig. 3A). UBE2N (also known as Ubc13) is a unique E2 ubiquitin-conjugating enzyme and plays an important role in host inflammatory responses (54). For example, a secreted *Shigella* effector, OspI, was reported to specifically target Ubc13 and deamidates Gln-100 to a glutamic acid residue, leading to the disruption of TRAF6-catalyzed poly-ubiquitylation. This results in suppressing the diacylglycerol → CBM → TRAF6 → NF-κB signaling pathway and dampens the host inflammatory responses (55). To validate the relevance of ROP18 and UBE2N, we expressed V5-ROP18\(^{\text{A83}}\) or V5-ROP18\(^{\text{A83-KD}}\) in 293T cells. Western blotting analysis showed that overexpression of ROP18\(^{\text{A83}}\) but not ROP18\(^{\text{A83-KD}}\) led to a significant reduction in the protein level of UBE2N (Fig. 6A), suggesting that the kinase activity of ROP18 plays an important role in ROP18-mediated UBE2N degradation. We then investigated whether ROP18 affects UBE2N expression *in vivo*. The data showed that, although infection with the WT RH strain significantly decreased the UBE2N expression relative to non-infection, infection with the ROP18-Ty1 RH strain resulted in a more significant decrease in the protein level of UBE2N (Fig. 6B). Together, these results suggested that UBE2N is a ROP18-targeting host protein.

**ROP18-mediated Smad1 Proteasomal Degradation via Phosphorylation**—Interference of the TGF-β signaling pathway has been shown to be highly associated with *Toxoplasma* infection (56). Accordingly, Smad1, one of the family members that act downstream of receptors of TGF-β family members (57), was identified as a substrate of ROP18 kinase in this study. To determine whether ROP18 interacted with Smad1, we performed the coimmunoprecipitation assay and observed that ROP18 could readily immunoprecipitate Smad1 in cotransfected cells (Fig. 7A). We then investigated the influence...
ence of ROP18 on Smad1 expression. The results showed that expression of ROP18^K83 but not ROP18^K83-KD markedly reduced the protein level of Smad1 (Fig. 7B) in a dose-dependent manner (Fig. 7C). Interestingly, the protein level of Smad1 was restored in the presence of a proteasome inhibitor, MG132 (Fig. 7D), suggesting that ROP18 phosphorylation-induced Smad1 degradation was mediated by the proteasome. To confirm that Smad1 could be phosphorylated by ROP18, we carried out an in vitro kinase assay with purified ROP18^K83 and ROP18^K83-KD proteins. The results clearly showed that GST-ROP18^K83, but not GST-ROP18^K83-KD, strongly phosphorylated the His6-tagged Smad1 protein (Fig. 7E).

To further investigate the molecular basis of ROP18-mediated Smad1 degradation, we sought to determine which residue(s) in Smad1 could be phosphorylated by ROP18. In previous studies, phosphorylation in the linker region of Smad1 has been shown to trigger its degradation (58, 59). The observation that ROP18 also induced Smad1 proteasomal degradation prompted us to test the hypothesis that ROP18 might utilize a similar mechanism to regulate Smad1 protein levels. Thus, we performed site-directed mutagenesis at Ser-187, Ser-195, Ser-206, and Ser-214 in the linker region, which were identified as the phosphorylation sites in previous studies (59). By testing different combinations of mutations at these Ser residues, we found that Ser-187 to Ala mutation blocked the reduction of Smad1 protein levels induced by ROP18 (Fig. 7F), suggesting that Ser-187 phosphorylation of Smad1 by ROP18 was responsible for its degradation. To verify that Smad1 Ser-187 was phosphorylated by ROP18, we examined the phosphorylation status of Smad1 Ser-187 by performing immunoblotting analysis with a commercial phospho-specific antibody against Smad1 Ser-187 in transfected cells. The results showed that, compared with the control vector, transfection of ROP18^K83 significantly increased the phosphorylation level of Smad1 Ser-187, especially considering that the Smad1 protein was strongly reduced by ROP18^K83 (Fig. 7G). In contrast, no significant difference was observed upon transfection of ROP18^K83-KD (Fig. 7G). To further determine whether ROP18 phosphorylates Smad1 at Ser-187 in vivo, HFF cells were infected with the WT RH, ROP18-KO RH, or ROP18-Ty1 RH strain. Immunoblotting analysis showed that as compared with non-infection, infection with the WT RH and ROP18-Ty1 RH strain resulted in increased phosphorylation levels of Smad1 Ser-187 accompanied by decreased Smad1 protein levels, whereas infection with ROP18-KO RH strain did not alter the phosphorylation status of Smad1 at Ser-187 and had no effect on Smad1 protein levels (Fig. 7H). These results suggested that ROP18 phosphorylates Smad1 Ser-187 to facilitate its degradation.

**DISCUSSION**

In this study, we performed phosphorylation reactions on a HuProt array to globally screen for host substrates of ROP18 kinase, which is a key determinant of parasite virulence. A number of novel putative host targets involved in various cellular functions were identified. Among these proteins, four candidates, p53, p38, UBE2N, and Smad1, were further validated as ROP18 substrates.

A key to the success of this study was the purification of active ROP18 kinase proteins from the budding yeast. Although the bacterial systems have been more popular for protein expression, they suffer from a lack of proper protein post-translational modifications, and overexpression of foreign proteins in bacteria often resulted in an insoluble or inactive form of the desired proteins (28, 60). Yeast cells combine the advantages of being single cells, such as fast growth and easy genetic manipulation, as well as eukaryotic features, including a secretory pathway leading to correct protein processing and post-translational modifications (61). Indeed, recombinant ROP18 proteins currently purified from E. coli are only suitable for immunity or structural analysis, requiring little or no activity (60, 62). A truncated ROP18 protein that corresponds to the kinase catalytic domain was successfully expressed in E. coli, but the recombinant protein had to be refolded to obtain bioactivity. The refolded recombinant protein was rather unstable and could not be obtained in sufficient amounts (28). To our knowledge, we have provided the first demonstration that by using a yeast system, the mature ROP18 protein with high kinase activity and satisfactory quantity was successfully purified. This finding paves a way for oncoming in-depth studies, such as crystal structure analysis of phosphorylated ROP18, in vitro kinase assays, and substrate screening.

Identification of key host targets of ROP18 is crucial for understanding the pathogenesis of *T. gondii*. So far the discovery of ROP18 substrates mainly relies on the yeast two-hybrid method, in which interactions are typically detected in the nucleus, thus restricting the types of interaction that can be detected. In addition, the two-hybrid approach detects protein-protein interaction but not the protein bioactivity (29). Protein microarray is a powerful tool for comprehensive...
screens of protein functions, which has been applied for global analysis of protein modified by ubiquitylation, SUMOylation, acetylation, and S-nitrosylation (17). Additionally, protein microarray has been expanded to identify kinase substrates (18–24). Whereas creating protein microarrays requires a specialized system, the arrays can be stored and saved for later use, providing a faster and cheaper detection tool for high-throughput studies. In this study, using the human protein microarray, we globally determined the substrates of ROP18 kinase and identified a total of 68 potential host targets.

*T. gondii* strictly relies on host cellular metabolism to obtain the energy and nutrients for its replication and survival (63). But how *T. gondii* modulates the metabolism of its host to create a more hospitable metabolic niche remains vague. Transcriptomics analysis has shown that infection of *T. gondii* results in alteration of protein expression in key metabolic pathways, as characterized by the down-regulation of mitochondrial respiratory chain and the metabolism of fatty acids, lipids, and xenobiotics (64). Interestingly, in this study, we found that the majority of ROP18 substrates are enriched in the metabolic process, suggesting an important role of ROP18 in manipulating the host cellular metabolism. In particular, ROP18 seems to regulate the host insulin signaling, which modulates the metabolism of glucose, lipids, proteins, and energy (65, 66), as several putative substrates take part in this pathway. *T. gondii* preferentially utilizes host glucose as a source for the synthesis of ATP, nucleic acid, proteins, and...
lipids and intracellular replication (67). Thus, ROP18-mediated insulin pathway might be beneficial for the metabolism of *T. gondii*.

Induction of apoptosis is a common host response to infection. Therefore, pathogens including *T. gondii* have developed strategies to hamper host cell apoptosis. Consistent with this notion, ROP18 has been shown to inhibit host cell apoptosis with a not yet known mechanism. Previous studies reported that *T. gondii* infection alters host MAPK signaling pathway (47, 48), which regulates multiple cellular processes, including apoptosis (68). Intriguingly, we identified several MAPK pathway effectors, including MAP3K5, MAPK9, MAPK10, MAPK11, PRKCA, and p53, as the putative ROP18 substrates. In addition, three substrates, PDPK1, GSK3β, and p53, are implicated in the PI3K/AKT pathway that are important for maintaining the cellular anti-apoptotic state (69). Moreover, host proteins FLT1 (70) and PRKRA (71) involved in apoptosis and cell growth were also identified as the ROP18 targets. Overall, our data suggest that ROP18 might regulate host cell apoptosis through multiple host signaling pathways and targets.

Host immunity limits the parasite growth. In turn, *T. gondii* interferes with the host immune-related signaling, enabling the parasite to evade the host immune response. ROP18 has been reported to modulate the NF-κB signaling pathway that is critical in regulating inflammation and innate immune responses to *T. gondii* infection (13). In agreement with this idea, host proteins UBE2N (72, 73) and RNF25 (74), which take part in NF-κB pathway, were identified as the ROP18 substrates, indicating that these proteins might be required for ROP18-mediated NF-κB signaling regulation. IFN-γ secretion is crucial for controlling *T. gondii* infection (75). *T. gondii* has been reported to down-regulate the expression of IRF1 (76, 77), a transcription factor that regulates most of the other half of IFN-γ-responsive genes (78). Intriguingly, we identified IRF1 as a potential substrate of ROP18, implying that *T. gondii* probably regulates IRF1/IFN-γ expression via ROP18 kinase.

Phosphorylation by protein kinases is a common way to regulate the complex signaling networks. Interestingly, we identified at least eight host kinases as ROP18 substrates, including CLK2, CSNK1G3, PDPK1, PRKCA, GSK3β, MAPK10, MAPK11, and MAPK9. All of these kinases are key regulators involved in multiple biological processes, including cell cycle, apoptosis, cell proliferation, immunity, and metabolism, to name a few (Fig. 3A). Bioinformatics analyses based on our dataset now suggest that ROP18 may serve as a master kinase modulating multiple host signaling pathways. Notably, ATF6β (12) and p65 (13) that have been reported to be the substrates of ROP18 were not identified in our assays. ATF6β was absent in the human ORF collection used to express the proteins for HuProt array fabrication, whereas p65 was available in our collection but its protein level was not detected on the HuProt, presumably due to failure in its purification (29).

Although the possibility of false positives or false negatives due to incorrect folding or an insufficient amount of some proteins on the array cannot be excluded (29), our follow-up validation of four substrates, p53, p38, UBE2N, and Smad1, confirmed the efficacy of the screening.

The central position of p53 occupied in the PPI network formed by ROP18 substrates indicates that p53 might be a key host target required for ROP18-dependent parasite virulence. Studies have reported that infection of *T. gondii* induces degradation of endogenous p53, although the mechanism is not clearly understood (45, 46). In this study, we found that p53 is a host target of ROP18 kinase, and overexpression of ROP18 induced p53 degradation. Combined with previous studies, our results indicate that *T. gondii* induces p53 degradation via active ROP18 kinase. ROP18 has been reported to inhibit the apoptosis of infected cells, thereby providing a stable environment for parasitic proliferation (41). Considering the important role of p53 in apoptosis, it is possible that ROP18 mediates p53 degradation and thus suppresses host cell apoptosis. In addition to its function in apoptosis, p53 also plays a critical role in innate immunity (43, 44). It has been reported that down-regulation of p53 results in impaired expression of genes involved in interferon or toll-like receptor signaling during viral infection (79, 80). Gadd45α is a downstream target of p53 (43). The deficiency of Gadd45α in mice results in impaired Th1 development due to the lack of p38 activation, IL-12, and CD40 production in dendritic cells and diminished Th1 immune response to *T. gondii* antigen (81). Therefore, it is also likely that during pathogen infection, ROP18 binds to and degrades p53, leading to down-regulation of Gadd45α expression, which in turn results in reduction of IL-12 and CD40 production, thereby conferring an immune-privileged microenvironment for parasite proliferation, but such a mechanism remains to be experimentally demonstrated.

The p38 MAPK pathways controlling gene expression and early immune response contribute to the infection and replication of *T. gondii* (47, 48). It has been reported that parasite invasion triggers p38 activation and drives IL-12 production through an association with TAB1 (51). Braun *et al.* (82) also reported that during *Toxoplasma* infection the dense granule protein GRA24 binds to p38 and promotes p38 auto-phosphorylation and nuclear translocation, which results in up-regulation of the transcription factors Egr-1 and c-Fos and the synthesis of cytokines IL-12 and MCP1. Parasite infection activates the p38 MAPK pathway; however, this activation is rapidly decreased thereafter (50), implying a feedback mechanism subverting the host p38 MAPK pathway may exist. Interestingly, in this study, we identified p38 as a host target of ROP18. Moreover, we found that ROP18 interacted with p38 and triggered its degradation. Our results indicate that ROP18 might be a key negative modulator of the p38 MAPK pathway that disrupts the autonomous host cell protecting early immune response.
Ubiquitylation is an important process modulating protein destruction. It has been reported that ROP18 induced ubiquitin-dependent degradation of host protein (13) indicates that ROP18 is involved in ubiquitylation-related signaling. Here, we demonstrated that UBE2N, a member of the E2 ubiquitin-conjugating enzyme family (52), is a host target of ROP18. Previous studies have shown that UBE2N is essential for the immune signaling. In thymocytes, UBE2N regulates NF-κB, MAPK, and TAK1 (TGF-β-activated kinase 1) signaling pathways and thus regulates T cell receptor-mediated signaling and innate immunity (52, 53, 73, 83). Conjugation of TRAF6 with UBE2N is necessary for the activation of TNF receptor-associated factor (TRAF)-dependent signal transduction pathways (NF-κB, JNK, and p38 MAPK) and inflammatory responses (73, 84). Given the critical role of UBE2N in innate and inflammatory responses, disruption of UBE2N by ROP18 may result in impaired immune responses, thus facilitating the intracellular growth of *Toxoplasma gondii*. Further studies are required to validate this hypothesis.

TGF-β signaling, which functions in cell proliferation, apoptosis, embryonic development, angiogenesis, and immunity, plays important roles in controlling *Toxoplasma* infection (56, 85). TGF-β1 is an important cytokine that has a dual role in the regulation of immune response against *T. gondii* infection as follows: induction of immune responses by development of Th17 lymphocytes and mucosal immunity and suppression of immune responses by inducing T regulatory cells, which restrict Th17 development, and inhibiting pro-inflammatory cytokine production, such as TNF-α (85). Smad1 is one of the members of the intracellular effectors of TGF-β signaling, which has important roles in cell proliferation, inflammation, and T cell differentiation (86–88). Smad1 is a mediator of bone morphogenetic protein signals, but it can also be activated by TGF-β1 (89). In this study, we identified for the first time that Smad1 is a target of ROP18, but its function and mechanisms underlying the parasite virulence remain to be defined. It has been reported that manipulation of host cell targets by *T. gondii* contributes to its proliferation (90). Considering the important role of Smad1 in cell proliferation, we determined whether targeting Smad1 affects *T. gondii* intracellular growth; however, the results showed that silencing Smad1 in HFF cells was not obviously beneficial for *T. gondii* replication (data not shown), implying that Smad1 might mediate parasite virulence via a mechanism that is distinct from regulating the parasite proliferation. Studies have been reported that Ids, the downstream targets of Smad1 (91), are pivotal regulators of lymphocyte differentiation and proliferation, particularly the CD8+ effector and memory T cells and CD4+ T cells (92–95). Our data showed that ROP18 interacted with Smad1 and prompted its proteasomal degradation. Therefore, it is possible that after parasite infection, ROP18 impairs the T cell development and function by down-regulating Smad1 and its downstream effectors Ids, and thus it facilitates an escape of *T. gondii* from the host immune system, but this hypothesis remains to be verified in the parasite-infected Smad1 mutant mouse model.

In summary, we report for the first time that with the use of a human proteome array, the substrates of *T. gondii* ROP18 kinase were systemically identified. Moreover, four important proteins, p53, p38, UBE2N, and Smad1 were validated as the host targets. Notably, we demonstrated that ROP18 phosphorylates Smad1 Ser-187 to promote its proteasome-dependent degradation. Functional analysis of the novel substrates of ROP18 kinase will be of benefit for understanding *Toxoplasma* virulence regulatory mechanisms mediated by ROP18 and providing potential targets for therapeutic intervention. The approaches utilized in this study may offer a new strategy for discovering novel host targets during host-pathogen interactions.

Acknowledgments—We thank Dr. Jianfei Hu (The Johns Hopkins University) and Zhihao Zhang (Sungkyunkwan University) for their technical assistance. We thank Professor Vern B. Carruthers (University of Michigan Medical School) for many helpful comments.

* This work was supported in part by National Natural Science Foundation of China Grants 81328014 and 31602040, National Science Foundation of Guangdong Province Grant 2015A030313105, Science and Technology Planning Project of Guangdong Province Grants 2014A020214002, 2013B021800243, and 2015A020210048, and National Institutes of Health Grant 1R01GM111514-02 (to H.Z.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

This article contains supplemental material.

|| Both authors contributed equally to this work.

To whom correspondence may be addressed: E-mail: zhouxw2@mail.sysu.edu.cn, E-mail: hzhu4@jhmi.edu, or E-mail: liaowq5@mail.sysu.edu.cn.

REFERENCES

1. Bilii, P., Della Strada, M., Pierro, A., Semprini, S., Tommasini, N., and Sambri, V. (2016) Three years retrospective analysis of the incidence of *Toxoplasma gondii* infection in pregnant women living in the Greater Romagna Area (North Eastern Italy). *Clin. Microbiol. Infect.* 22, 572
2. Shen, G., Wang, X., Sun, H., and Gao, Y. (2016) Seroprevalence of *Toxoplasma gondii* infection among HIV/AIDS patients in Eastern China. *Korean J. Parasitol.* 54, 93–96
3. Dubey, J. P. (2008) The history of *Toxoplasma gondii*—the first 100 years. *J. Eukaryot. Microbiol.* 55, 467–475
4. Boothroyd, J. C. (2009) *Toxoplasma gondii*: 25 years and 25 major advances for the field. *Int. J. Parasitol.* 39, 935–946
5. Boothroyd, J. C., and Dubremetz, J. F. (2008) Kiss and spit: the dual roles of *Toxoplasma* rhoptries. *Nat. Rev. Microbiol.* 6, 79–88
6. Saeij, J. P., Boyle, J. P., Coller, S., Taylor, S., Sibley, L. D., Brooke-Powell, E. T., Ajieoka, J. W., and Boothroyd, J. C. (2006) Polymorphic secreted kinases are key virulence factors in toxoplasmosis. *Science* 314, 1780–1783
7. Taylor, S., Barragan, A., Wu, C., Fux, B., Fentress, S. J., Tang, K., Beatty, W. L., Haji, H. E., Jerome, M., Behnke, M. S., White, M., Wootten, J. C., and Sibley, L. D. (2006) A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen *Toxoplasma gondii*. *Science* 314, 1780–1783
8. Bradley, P. J., Ward, C., Cheng, S. J., Alexander, D. L., Coller, S., Coombs, G. H., Dunn, J. D., Ferguson, D. J., Sanderson, S. J., Wastling, J. M., and Boothroyd, J. C. (2005) Proteomic analysis of rhoptry organelles reveals
many novel constituents for host-parasite interactions in Toxoplasma gondii. J. Biol. Chem. 280, 34245–34258.

9. Sinai, A. P. (2007) The Toxoplasma kinase ROP18: an active member of a degenerate family. PLoS Pathog. 3, e16.

10. Steinfeldt, T., Koenen-Waisman, S., Tong, L., Pawlowski, N., Lamkemeyer, T., Sidney, L. D., Hunn, J. P., and Howard, J. C. (2010) Phosphorylation of mouse immunity-related GTPase (IRG) resistance proteins is an evasion strategy for virulent Toxoplasma gondii. PLoS Biol. 8, e1000576.

11. Fentress, S. J., Behnke, M. S., Dunay, I. R., Mashayekhi, M., Rommerrer, L. M., Fox, B. A., Bizik, D. J., Taylor, G. A., Turk, B. E., Lichti, C. F., Townsend, R. R., Qiu, W., Hui, R., Beatty, W. L., and Sidney, L. D. (2010) Phosphorylation of immunity-related GTPases by a Toxoplasma gondii-secreted kinase promotes macrophage survival and virulence. Cell Host Microbe 8, 484–495.

12. Yan, G., Zhu, J., Xie, Z., Mueller, C., Kamiyama, N., Saiga, H., Kudo, E., Kimura, T., Okamoto, T., Okuyama, M., Kayama, H., Nagamune, K., Takashima, S., Matsuura, Y., Soldati-Favre, D., and Takeda, K. (2011) ATP6 is a host cellular target of the Toxoplasma gondii virulence factor ROP18. J. Exp. Med. 208, 1533–1546.

13. Du, J., An, R., Chen, L., Shen, Y., Chen, Y., Cheng, J., Zhang, A., Yu, L., Chu, D., Shen, Y., Luo, Q., Chen, H., Wan, L., Li, M., et al. (2014) Toward a high-throughput virulence factor ROP18 promotes host NF-κB pathway by promoting p65 degradation. J. Biol. Chem. 289, 12578–12592.

14. Cheng, L., Shen, Y., Chen, L., Shen, Y., An, R., Luo, Q., and Du, J. (2012) Interactions between the ROP18 kinase and host cell proteins that aid in the parasitism of Toxoplasma gondii. Acta Trop. 122, 255–260.

15. Lin, Y. Y., Luo, J. Y., Zhang, J., Walter, D., Wang, D., Wan, J., Tao, S. C., Qian, J., Zhao, Y., Boeke, J. D., Berger, S. L., and Zhu, H. (2009) Protein array microanalysis reveals that NUK4 controls key metabolic target regulating gluconeogenesis. Cell 136, 1073–1084.

16. Lu, J. Y., Yin, Y. L., Qian, J., Tao, S. C., Zhu, J., Pickart, C., and Zhu, H. (2008) Functional dissection of a HECT ubiquitin E3 ligase. Mol. Cell. Proteomics 7, 35–45.

17. Sutanday, F. X., Qian, J., Chen, C. S., and Zhu, H. (2013) Overview of protein microarrays. Curr. Protoc. Protein Sci. Chapter 27, Unit 27.11.

18. Newman, R. H., Wu, J., Rho, H. S., Xie, Z., Woodard, C., Neiswinger, J., Cooper, C., Shirley, M., Clark, H. M., Hu, S., Hwang, W., Jeong, J. S., Wu, G., Lin, J., Gao, X., et al. (2013) Construction of human activity-based phosphorylation networks. Mol. Syst. Biol. 9, 655.

19. Hu, J., Rho, H. S., Newman, R. H., Wang, W., Neiswinger, J., Zhu, H., Zhang, J., and Qian, J. (2014) Global analysis of phosphorylation networks in humans. Biochem. Biophys. Acta 1844, 224–231.

20. Woodard, C. L., Goodwin, C. R., Wan, J., Xia, S., Newman, R., Hu, J., Zhang, J., Haywood, D. J., Qian, J., and Zhu, H. (2013) Profiling the dynamics of a human phosphoproteome reveals new components in HGF-c-Met signaling. PLoS ONE 8, e72671.

21. Woodard, C., Shamay, M., Liao, G., Zhu, J., Ng, A. N., Li, R., Newman, R., Rho, H. S., Hu, J., Wan, J., Qian, J. H., and Newman, S. D. (2012) Phosphorylation of the chromatin binding domain of KSHV LANA. Mol. Cell. Proteomics 11, 0111.016253.

22. Hu, S., Xie, Z., Onishi, A., Yu, X., Jiang, L., Lin, J., Rho, H. S., Woodard, C., Wang, H., Jeong, J. S., Long, S., He, X., Wade, H., Blackshaw, S., Qian, J., and Zhu, H. (2009) Profiling the human protein–DNA interaction reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 139, 610–622.

23. Ranganathan, E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., and Smyth, G. K. (2015) limma powers differential expression analyses for RNA-seq and microarray studies. Nucleic Acids Res. 43, e47.

24. Yang, Z., Ahn, H. J., Park, Y. H., and Nam, H. W. (2016) Atf1 inhibits STAT6 signaling of host ARPE-19 cells infected with Toxoplasma gondii. Korean J. Parasitol. 54, 31–38.

25. Enarson, M. B., Pugacheva, E. N., and Orfínck, R. J. (2007) Identification of protein–protein interactions with glutathione-S-transferase (GST) fusion proteins. CSH Protoc. 2007, pdb.top1.

26. Zhou, X. W., Mudannayake, M., Green, M., Gigena, M. S., Wang, G., Chen, R. F., and Rogers, T. B. (2007) Proteomic studies of PP2A-B56-γ phosphatase complexes reveal phosphorylation-regulated partners in cardiac local signaling. J. Proteome Res. 6, 3433–3442.

27. Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., Simonovic, M., Roth, A., Santos, A., Tsafou, K. P., Kuhn, M. B., Huson, D. M., Fettweis, S., Caudron, C., Nussel, V. M., and Bork, P. (2011) BioPlex2: a database for human protein–protein interactions with glutathione-S-transferase (GST) fusion proteins. CSH Protoc. 2011, e72671.

28. Hoa, L., Kulaberoglu, Y., Gundogdu, R., Cook, D., Mavis, M., Gomez, V., and Hergovich, A. (2016) The characterisation of LAT52 kinase regulation in Hippo-YAP signalling. Cell. Signal. 28, 488–497.

29. Wu, L., Wang, X., Li, Y., Liu, Y., Su, D., Fu, T., Guo, F., Gu, L., Jiang, X., Chen, S., and Cao, J. (2016) Toxoplasma gondii ROP18: potential to manipulate host cell mitochondrial apoptosis. Parasitol. Res. 115, 2415–2422.

30. Sakpota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M. G., Grauer, M., Hoffmann, M., Schapp, G., Steegmaier, M., Cohen, P., and Alesci, D. R. (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem. J. 401, 29–38.

31. Kruse, J. P., and Gu, W. (2009) Modes of p53 regulation. Cell 137, 609–622.

32. Miciak, J., and Bunz, F. (2016) Long story short: p53 mediates innate immunity. Biochem. Biophys. Acta 1855, 220–227.

33. Brunet, J., Pfaff, A. W., Abidi, A., Unoki, M., Nakamura, Y., Guinard, M., Klein, J. P., Candolfi, E., and Mousli, M. (2008) Toxoplasma gondii exploits UHRF1 and induces host cell cycle arrest at G2 to enable its proliferation. Cell. Microbiol. 10, 908–920.

34. Bougourd, A., Durandau, E., Brenier-Pinchart, M. P., Ortet, P., Barakat, M., Kieffer, S., Curt-Varesano, A., Curt-Berti, R. L., Bastien, O., Coute, Y., Pelloux, H., and Hakimi, M. A. (2013) Host cell subversion by
Protein Microarray Identifying Novel ROP18 Kinase Substrates

Toxoplasma GRA16, an exported dense granule protein that targets the host cell nucleus and alters gene expression. *Cell Host Microbe* **13**, 489–500

Choi, J. Y., Ahn, M. H., Song, H. O., Choi, J. H., Ryu, J. S., Min, D. Y., and Cho, M. H. (2006) Involvement of MAPK activation in chemokine or COX-2 productions by Toxoplasma gondii. *Korean J. Parasitol.* **44**, 19, 27–30.

Quan, J. H., Chu, J. Q., Kwon, J., Choi, I. W., Ismail, H. A., Zhou, W., Cha, G. H., Zhou, Y., Yuk, J. M., Jo, E. K., and Lee, Y. H. (2015) Intracellular networks of the PI3K/AKT and MAPK pathways for regulating Toxoplasma gondii-induced IL-23 and IL-12 production in human THP-1 cells. *PLoS ONE* **10**, e0141550

Zarubin, T., and Han, J. (2005) Activation and signaling of the p38 MAPK pathway. *Cell Res.* **15**, 11–18

Vanacore, N., Boussou, M., Pasin, J., and Aubert, D. (2003) Activation of the cellular mitogen-activated protein kinase pathways ERK, JNK and MKK during Toxoplasma gondii invasion. *Parasite* **10**, 59–64

Kim, L., Del Rio, L., Butcher, B. A., Mogensen, T. H., Paludan, S. R., Flavell, R. A., and Denkers, E. Y. (2005) p38 MAPK autophosphorylation drives macrophage IL-12 production during intracellular infection. *J. Immunol.* **174**, 1819. 1824–1834

Chen, J., Hao, L., Li, C., Ye, B., Du, Y., Zhang, H., Long, B., Zhu, P., Liu, B., Matsuura, T., Takeuchi, O., and Akira, S. (2006) Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. *Nat. Immunol.* **7**, 962–970

Chen, J., Hao, L., Li, C., Ye, B., Du, Y., Zhang, H., Long, B., Zhu, P., Liu, B., Yang, L., Li, P., Tian, Y., and Fan, Z. (2015) The extracellular reticulin network adaptor protein ERADp initiates Nk cell activation via the Ubc13-mediated NF-κB pathway. *J. Immunol.* **194**, 1292–1303

Cheng, J., Fan, Y. H., Xu, X., Zhang, H., Dou, J., Tang, Y., Zhong, X., Rojas, Y., Yu, Y., Zhao, Y., Vasudevan, S. A., Zhang, H., Nuchtern, J. G., Kim, E. S., Chen, X., Lu, F., and Yang, J. (2014) A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways. *Cell Death Dis.* **5**, e1079

Sanada, T., Kim, M., Minamino, T., Suzuki, M., Ogawa, M., Oyama, A., Ashida, H., Kobayashi, T., Koyama, T., Nagai, S., Shibata, Y., Gohda, J., Inoue, J., Mizushima, T., and Sasakawa, C. (2012) The Shigella flexneri finger protein AO7 supports NF-κB/Rel-mediated innate immunity by enhancing activation of NFκB-target genes. *Cell. Microbes Infect.* **16**, 778–787

Massagué, J. (1998) TGF-β signal transduction. *Annu. Rev. Biochem.* **67**, 753–791

Fuentesabía, L. C., Elvers, E., Ikeda, A., Hurtado, C., Kuroda, H., Pera, E. M., and De Robertis, E. M. (2007) Integrating patterning signals: Wnt/GSK3β and TGF-β/Smad6/7 transduction pathways. *Cell Biol. Chem.* **288**, 34963–34980

Sapkota, G., Aparicio, C., Spagnoli, F. M., Brivanlou, A. H., and Massague, J. (2000) The PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. *Oncotarget* **10**, 18372–18384

Koch, S., Tugues, S., Li, X., Guérand, L., and Claesson-Welsh, L. (2011) Signal transduction by vascular endothelial growth factor receptors. *Biochem. J.* **437**, 169–183

Peters, G. A., Li, S., and Sen, G. C. (2006) Phosphorylation of specific serine residues in the PKR activation domain of PACT is essential for its ability to mediate apoptosis. *J. Biol. Chem.* **281**, 35129–35136

Yu, Y., Wang, X., and Rape, M. (2008) Building ubiquitin chains: E2 enzymes at work. *Nat. Rev. Mol. Cell Biol.* **10**, 755–764

Lamothe, B., Besse, A., Campos, A. D., Webster, W. K., Wu, H., and Darnay, B. G. (2007) Site-specific Lys-63-linked tumour necrosis factor receptor-associated factor-associator factor 6 ubiquitination is a critical determinant of IL-6 kinase activation. *J. Biol. Chem.* **282**, 4102–4112

Asamitsu, K., Tetsuka, T., Kanazawa, S., and Okamoto, T. (2003) RIP1 finger protein AOT supports NF-κB-mediated signal transduction by interacting with the transactivation domain of the p65 subunit. *J. Biol. Chem.* **278**, 26879–26887

Sa, Q., Ochiia, E., Tiwari, A., Perkins, D., Mullins, J., Gehman, M., Huckle, W., Eyestone, W. H., Saunders, T. L., Shelton, B. J., and Suzuki, Y. (2015) Cutting edge: IFN-γ produced by brain-resident cells is crucial to control cerebral infection with Toxoplasma gondii. *J. Immunol.* **195**, 796–800

Lang, C., Algner, M., Beinert, N., Gross, U., and Lüder, C. G. (2006) Diverse mechanisms employed by Toxoplasma gondii to inhibit IFN-γ-induced major histocompatibility complex class II gene expression. *Microbes Infect.* **8**, 1994–2005

Lüder, C. G., Walter, W., Beuerle, B., Maerue, M. J., and Gross, U. (2001) Toxoplasma gondii down-regulates MHC class II gene expression and antigen presentation by murine macrophages via interference with nuclear translocation of STAT1α. *Eur. J. Immunol.* **31**, 1475–1484

Ramsauer, K., Farlik, M., Zupkovitz, G., Seiser, C., Kroeber, A., Hauser, H., and Decke, T. (2007) Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-γ-inducible gbp2 gene. *Proc. Natl. Acad. Sci. U.S.A.* **104**, 2849–2854

Yuan, L., Chen, Z., Song, S., Wang, S., Tian, C., Xing, G., Chen, X., Xiao, Z. X., He, F., and Zhang, L. (2015) p53 degradation by a coronavirus papain-like protease suppresses type I interferon signaling. *J. Biol. Chem.* **290**, 3172–3182

Heinrich, A., Haarmann, H., Zahradnik, S., Frenzel, K., Schreiber, F., Klastersky, J., Heyl, K. A., Endres, A. S., Schmidtke, M., Hofmann, J., and Sleevogt, H. (2016) Moraxella catarrhalis decreases antiviral innate immune responses by down-regulation of TL1A via inhibition of p53 in human bronchial epithelial cells. *FASEB J.* **30**, 2426–2434

Jiménez-López, J., Yakovleva, D., Fornace, A. J., and Ashwell, D. J. (2007) Gadd45α regulates p38-dependent dendritic cell cytokine production and Th1 differentiation. *J. Immunol.* **178**, 1415–1428

Braun, L., Brenier-Pinchart, M. P., Bogovski, M., Curt-Varesano, A., Curt-Berlini, R. L., Hussain, T., Kieffer-Jaquind, S., Coute, Y., Pellow, H., Tardieu, I., Sharma, A., Beirn, H., Bougdour, A., and Hakimi, M. A. (2013) A Toxoplasma dense granule protein, GRA24α, modulates the early
immune response to infection by promoting a direct and sustained host p38 MAPK activation. J. Exp. Med. 210, 2071–2086
83. Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J., and Chen, Z. J. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346–351
84. Fukushima, T., Matsuzawa, S., Kress, C. L., Bruey, J. M., Krajewska, M., Lefebvre, S., Zapata, J. M., Ronai, Z., and Reed, J. C. (2007) Ubiquitin-conjugating enzyme Ubc13 is a critical component of TNF receptor-associated factor (TRAF)-mediated inflammatory responses. Proc. Natl. Acad. Sci. U.S.A. 104, 6371–6376
85. Zare-Bidaki, M., Assar, S., Hakimi, H., Abdollahi, S. H., Nosratabadi, R., Kennedy, D., and Arababadi, M. K. (2016) TGF-β/H9252 in toxoplasmosis: friend or foe? Cytokine 86, 29–35
86. Liu, H., Jia, D., Li, A., Chau, J., He, D., Ruan, X., Liu, F., Li J., He, L., and Li, B. (2013) p53 regulates neural stem cell proliferation and differentiation via BMP-Smad1 signaling and Id1. Stem Cells Dev. 22, 913–927
87. Besson-Fournier, C., Gineste, A., Latour, C., Gourbeyre, O., Meynard, D., Martin, P., Oswald, E., Coppin, H., and Roth, M. P. (2016) Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B. Blood, blood-2016-10-748541
88. Gandhi, R., Kumar, D., Burns, E. J., Nadeau, M., Dake, B., Laroni, A., Kozoriz, D., Weiner, H. L., and Quintana, F. J. (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat. Immunol. 11, 846–853
89. Miyazaki, M., Miyazaki, K., Chen, S., Ito, M., Miller, M., Lu, L. F., Varki, N., Chang, A. N., Brodie, D. H., and Murre, C. (2014) Id2 and Id3 maintain the regulatory T cell pool to suppress inflammatory disease. Nat. Immunol. 15, 767–776
90. Yang, C. Y., Best, J. A., Knell, J., Yang, E., Sheridan, A. D., Jesionek, A. K., Li, H. S., Rivera, R. R., Lind, K. C., D’Cruz, L. M., Watowich, S. S., Murre, C., and Goldrath, A. W. (2011) The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8(+) T cell subsets. Nat. Immunol. 12, 1221–1229